Infectious Disease
Shionogi starts Phase I trial of Covid-19 antiviral in Japan
Shionogi has commenced a Phase I trial in Japan to investigate S-892216 for the treatment of Covid-19. The firm successfully…
NIAID starts subject enrolment in mRNA universal influenza vaccine trial
The National Institute of Allergy and Infectious Diseases (NIAID) has started enrolment of volunteers at Duke University to test its…
Codagenix initiates new study of live-attenuated vaccine in RSV
Codagenix is moving its rational virus design platform forward with a new Phase I trial of its live attenuated respiratory…
Novavax reports positive results from Phase II study of vaccine candidates
Novavax has reported positive Phase II topline results evaluating its Covid-Influenza Combination (CIC), stand-alone influenza and high-dose Covid vaccine candidates.…
HOOKIPA doses first patient in trial of HB-400 for chronic hepatitis B
HOOKIPA Pharma has dosed the first patient in a Phase I clinical trial of its investigational, non-replicating arenaviral HB-400 vaccine…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Inovio’s HPV vaccine demonstrates immunological benefits in RRP
Plymouth Meeting, US-based Inovio announced new data from a Phase I/II trial investigating INO-3107 in patients with HPV-associated recurrent respiratory…
Enanta reports positive data from Phase II Covid-19 therapy trial
Enanta Pharmaceuticals has reported positive top-line results from the SARS-Cov-2 PRotease INhibitor Treatment (SPRINT) Phase II clinical trial of EDP-235…
Taiwan FDA clears Senhwa’s IND to start Phase II Covid-19 therapy trial
Taiwan FDA has granted clearance for Senhwa Biosciences’ investigational new drug (IND) application to initiate a Phase II clinical trial…
RNAimmune receives FDA IND approval for Covid-19 booster vaccine trial
Sirnaomics subsidiary RNAimmune has secured approval from the US Food and Drug Administration (FDA) for its investigational new drug (IND)…
AlloVir reports positive data from multi-virus T cell therapy trial
AlloVir has reported positive long-term, follow-up data from the Phase ll trial of multi-virus T cell therapy posoleucel to prevent…